Immune, Gut & Longevity
Best Peptides for IBD (Crohn's & Ulcerative Colitis): Evidence (2026)
An evidence-first ranking of the peptides studied for inflammatory bowel disease — BPC-157, KPV, thymosin alpha-1 and larazotide acetate — separating decades of rodent colitis data from the near-total absence of human IBD trials.
BPC-157 colitisKPV IBDthymosin alpha-1larazotide leaky gutCrohn's & UC evidence
The quick verdict
No peptide is a proven IBD therapy — none has a completed, published human RCT in Crohn's disease or ulcerative colitis. We rank BPC-157, KPV, thymosin alpha-1 and larazotide by the strength of their gut-specific evidence, and separate mechanism from proof.
- Best overall
- BPC-157 — Deepest, most gut-specific preclinical record of any peptide here — discovered in gastric juice, decades of rodent colitis/fistula/anastomosis healing data. Still Grade C: its one human UC trial was never published.
- Best value
- KPV — The most mechanistically elegant and independently replicated murine colitis evidence, targeting inflamed epithelium via PepT1 — but zero human trials, so any 'value' is theoretical.
- Best for Patients weighing a candidate with a real human-safety pedigree earned elsewhere
- Thymosin alpha-1 — The only candidate approved as a drug somewhere (hepatitis B/C, cancer adjuvant) with multiple human RCTs and a clean tolerability record — though its IBD evidence is preclinical plus old in-vitro data, and it can conflict with immunosuppression.
How we evaluated
We ranked peptides by the strength of their IBD-specific evidence, weighting completed, published human trials in Crohn's or ulcerative colitis above preclinical colitis models, and preclinical data above mechanism or anecdote. Human-trial pedigrees earned in other diseases are noted but do not count as IBD evidence. Grades are assigned honestly — no peptide earned above Grade C for IBD, and we flag where marketing outruns proof.
- Human IBD trial evidence. Completed, published, controlled trials in Crohn's disease or ulcerative colitis — the highest weight. None of the four candidates has one.
- Preclinical colitis data. Depth, consistency and independent replication of rodent colitis/gut-injury models and relevant cell-culture mechanism.
- Mechanistic plausibility for IBD. Whether the peptide targets a validated IBD driver — barrier repair, NF-kB/cytokine suppression, or immune tolerance.
- IBD-specific safety & legal risk. Cancer-angiogenesis, immunosuppression conflicts, purity hazards, and 2026 FDA/WADA status relevant to IBD patients.
Rating scale: 1-5 stars, in 0.5 increments, reflecting IBD-specific evidence strength and safety — not general popularity. A high rating still means preclinical-only for IBD.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | BPC-157 | C | 3.0 | Understanding the peptide with the deepest gut-specific preclinical rationale — while recognizing it remains unproven in humans for IBD | Not FDA-approved; sold research-use-only |
| 2 | KPV | C | 2.5 | Appreciating the most disease-targeted preclinical mechanism — while recognizing it has never been tested in a single human | Not FDA-approved; sold research-use-only |
| 3 | Thymosin alpha-1 | C | 2.5 | Those weighing a candidate with a genuine human-safety pedigree earned in other diseases, while noting its IBD evidence is preclinical | Approved abroad (Zadaxin); not FDA-approved for IBD |
| 4 | Larazotide acetate | D | 2.0 | Understanding why the most-studied gut-barrier peptide still does not support a 'seal the gut, cure IBD' claim | Unapproved everywhere; research-use-only |
BPC-157
Deepest gut-specific rodent record; one unpublished human UC trial
BPC-157 ranks first for IBD because it is the only peptide here that was literally discovered in the gut — a synthetic 15-amino-acid fragment of a protein in human gastric juice — and it carries the deepest, most GI-specific preclinical record. In rodents it heals gastric ulcers, cysteamine- and TNBS-induced colitis, colocutaneous and ileoileal fistulae, anastomoses and NSAID-induced intestinal lesions, often healing colitis and an intestinal anastomosis in the same animal. Its reported stability in gastric juice underlies the rationale for oral dosing in gut indications. But this is where hype outruns proof: Croatian developer Pliva advanced BPC-157 (as PL 14736) into a Phase 2 ulcerative-colitis trial in the early 2000s, yet those results were never published in a peer-reviewed journal, and there is no completed, published, controlled human IBD trial. Total published human exposure across all indications is only a few dozen subjects in uncontrolled pilots. So IBD is simultaneously BPC-157's strongest case and its weakest. The dominant IBD-specific concern is mechanistic: BPC-157 is pro-angiogenic via VEGFR2/EGR-1, and IBD itself elevates colorectal-cancer risk, making chronic angiogenesis in an inflamed, dysplasia-prone colon a plausible, unstudied hazard.
Strengths
- Deepest and most GI-specific preclinical record of any peptide here — colitis, fistula, anastomosis and ulcer healing in multiple rodent models
- Discovered in gastric juice; reported gastric stability supports oral use for luminal gut targets
- Favorable animal toxicology (no lethal dose established up to 20 mg/kg in rats) and no adverse events in small human safety pilots
Weaknesses
- Its one human IBD trial (PL 14736 Phase 2 UC) was never published — no reportable human efficacy evidence
- Pro-angiogenic via VEGFR2/EGR-1, a biologically plausible tumor-angiogenesis hazard in a cancer-prone IBD colon
- Prohibited at all times in sport (WADA S0); FDA-unapproved and in a compounding grey zone
- Best for
- Understanding the peptide with the deepest gut-specific preclinical rationale — while recognizing it remains unproven in humans for IBD
- Pricing
- Not FDA-approved; sold research-use-only
Source: Józwiak M, et al., Pharmaceuticals 2025 (PMC11859134)
KPV
Elegant, replicated murine colitis via PepT1 — but zero human data
KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH, has the most mechanistically elegant and independently replicated preclinical colitis evidence of any peptide here. In the foundational study, oral KPV attenuated both DSS- and TNBS-induced colitis in mice — reducing weight loss, colonic myeloperoxidase, and mucosal IL-6, IL-1-beta, TNF-alpha and IFN-gamma — with NF-kB inhibition confirmed in human intestinal epithelial and T-cell lines. An independent group corroborated benefit in two murine IBD models, and targeted oral nanoparticle delivery normalized TNF-alpha, colon length, MPO and histology toward healthy controls in DSS colitis. Most strikingly, KPV reduced colitis-associated tumor burden in an AOM/DSS model — an effect abolished in PepT1-knockout mice, confirming the transporter-dependent mechanism. The targeting logic is appealing: PepT1 is low in healthy colon but up-regulated in inflamed IBD epithelium, so KPV concentrates where the disease is, and unlike alpha-MSH it causes no pigmentation or appetite effects. The problem is stark: KPV has never been tested in a human clinical trial for IBD or anything else, with no registered human trials as of mid-2026. Every human use is extrapolation from mice, and no human safety profile exists.
Strengths
- Independently replicated benefit across DSS and TNBS murine colitis, plus a targeted-delivery nanoparticle study normalizing colitis markers
- Disease-targeted mechanism: PepT1 up-regulation in inflamed IBD epithelium concentrates KPV where inflammation is
- Reduced (rather than promoted) colitis-associated tumor burden in an AOM/DSS model — reassuring for IBD's cancer-risk concern
Weaknesses
- Zero human clinical trials for IBD or any indication — all evidence is mouse/cell, so no human safety or efficacy data exist
- Grey-market 'use' rests entirely on animal extrapolation, with purity and contamination hazards
- Falls under WADA S0 as a non-approved substance; FDA-unapproved and in a compounding grey zone
- Best for
- Appreciating the most disease-targeted preclinical mechanism — while recognizing it has never been tested in a single human
- Pricing
- Not FDA-approved; sold research-use-only
Source: Dalmasso G, et al., Gastroenterology 2008 (PMID 18061177)
Thymosin alpha-1
Approved as a drug elsewhere; IBD evidence is preclinical plus old in-vitro data
Thymosin alpha-1 (thymalfasin; brand Zadaxin) is the only peptide here that is an approved drug somewhere — licensed for chronic hepatitis B/C and as a cancer immunoadjuvant in more than 30 countries, with multiple human RCTs and a clean tolerability record. That gives it a human-safety pedigree the others lack. For IBD specifically, however, the evidence is preclinical plus a thin slice of old human laboratory work. In DSS and DSS-plus-anti-CTLA-4 colitis models in mice, thymosin alpha-1 partially prevented weight loss, improved survival, reduced histologic inflammation, lowered MPO, TNF-alpha, IL-1-beta and IL-17A/F, raised IL-10, and restored barrier integrity — all via the IDO1 tolerogenic pathway and Treg promotion, with protection abolished in IDO1-deficient mice. Notably, in the same study it did not blunt anti-tumor immunity. The human IBD data are limited to a 1980 study of peripheral T-lymphocytes from 45 Crohn's and 23 UC patients showing thymosin fraction-5 corrected several immune-marker abnormalities in vitro — early evidence, but in-vitro only, not a treatment trial. There is no completed human IBD efficacy RCT, and its largest definitive human trial (the 1,089-patient TESTS sepsis RCT) was negative — a reminder that promising immunomodulation does not guarantee clinical benefit.
Strengths
- Only candidate approved as a drug somewhere, with multiple human RCTs and a well-characterized, clean tolerability profile (<1% drug-related adverse events)
- Preclinical colitis benefit via a coherent tolerogenic mechanism (IDO1/Treg/IL-10), abolished in IDO1-deficient mice
- In colitis models it did not blunt anti-tumor immunity — a favorable safety nuance for immunomodulation
Weaknesses
- No completed human IBD efficacy RCT; the only human IBD data are 1980-era in-vitro immune-marker work, not a treatment trial
- Augments Th1/CD8 and dendritic-cell activity — a relative contraindication in deliberate immunosuppression, overlapping with many IBD patients on immunosuppressants
- Its largest definitive human trial (TESTS sepsis RCT) was negative, cautioning against assuming clinical benefit from immunomodulation
- Best for
- Those weighing a candidate with a genuine human-safety pedigree earned in other diseases, while noting its IBD evidence is preclinical
- Pricing
- Approved abroad (Zadaxin); not FDA-approved for IBD
Source: Romani L, et al., Life Science Alliance 2020 (PMC7441522)
Larazotide acetate
Most advanced gut peptide — but never tested for IBD, and Phase 3 failed in celiac
Larazotide (AT-1001, INN-202) is the most clinically advanced gut peptide ever developed — an oral, locally acting octapeptide that antagonizes the zonulin pathway to seal tight junctions. It has at least four placebo-controlled RCTs in celiac disease, where 0.5 mg three times daily reproducibly reduced patient-reported GI symptoms in the 342-patient CeliAction Phase 2b. Yet three facts cap its IBD ranking. First, it has never been tested for efficacy in Crohn's or ulcerative colitis — its human program was celiac-specific, and 'CD' in some summaries means celiac disease, not Crohn's, a common point of confusion. Second, even the objective barrier endpoint failed in celiac: across pooled RCTs, larazotide did not significantly beat placebo on the urinary lactulose-to-mannitol permeability ratio, the very mechanism it is sold on. Third, its pivotal Phase 3 trial (CeDLara, NCT03569007) was discontinued in June 2022 for futility — the Phase 2b symptom signal did not replicate, calling the magnitude and centrality of the zonulin hypothesis into question. For IBD, larazotide rests only on shared mechanism (zonulin and permeability are elevated in IBD) plus animal and ex-vivo barrier-repair data such as ischemia-injured porcine jejunum — Grade C at best, and Grade D for any 'leaky-gut cure' marketing. Its safety in trials was excellent, with negligible systemic absorption, but for IBD it is safe yet unproven.
Strengths
- The most clinically advanced gut peptide, with at least four placebo-controlled celiac RCTs and an excellent trial safety record
- Negligible systemic absorption (plasma below quantification even at 36 mg), making systemic drug interactions unlikely
- Targets a validated IBD-relevant driver — zonulin/permeability is elevated in both Crohn's and ulcerative colitis
Weaknesses
- Never tested for efficacy in Crohn's or ulcerative colitis — its entire human program was celiac-specific
- Failed the objective permeability endpoint in celiac and had its pivotal Phase 3 discontinued for futility in June 2022
- For IBD it rests only on shared mechanism plus animal/ex-vivo data — Grade C at best, Grade D for 'leaky-gut cure' claims
- Best for
- Understanding why the most-studied gut-barrier peptide still does not support a 'seal the gut, cure IBD' claim
- Pricing
- Unapproved everywhere; research-use-only
Source: Hoilat GJ, et al., meta-analysis 2022 (PMID 34339872)
Feature comparison
| Feature | BPC-157 | KPV | Thymosin alpha-1 | Larazotide acetate |
|---|---|---|---|---|
| Human IBD trial | Unpublished Phase 2 UC | None | In-vitro only (1980) | None (celiac only) |
| Preclinical colitis data | Extensive | Replicated (DSS + TNBS) | DSS + ICI colitis models | Mechanistic / ex-vivo |
| Primary IBD mechanism | Barrier repair + angiogenesis | PepT1-targeted NF-kB suppression | IDO1/Treg tolerance induction | Zonulin/tight-junction repair |
| IBD-specific safety flag | Pro-angiogenic (cancer risk) | Reduced tumor burden in model | Immune stimulation vs suppressants | Safe but unproven for IBD |
Frequently asked
Is there any peptide proven to treat Crohn's disease or ulcerative colitis in humans?
No. As of 2026, no peptide has a completed, published, positive human randomized controlled trial in inflammatory bowel disease. The best human-trial pedigrees — larazotide acetate and thymosin alpha-1 — were earned in other diseases (celiac disease and chronic hepatitis B), and larazotide, the most relevant gut-barrier peptide, failed its pivotal Phase 3 trial in celiac disease in 2022. The peptides discussed for IBD rest overwhelmingly on rodent colitis models and cell culture. The proven, guideline-endorsed IBD therapies are the biologics and small molecules — anti-TNFs, vedolizumab, ustekinumab, risankizumab, JAK inhibitors and S1P modulators — all with Grade-A human evidence.
BPC-157 was in clinical trials for IBD — doesn't that count as human evidence?
Only very weakly. BPC-157, developed as PL 14736 by the Croatian firm Pliva, did enter a Phase 2 ulcerative-colitis program in the early 2000s. But the results were never published in a peer-reviewed journal, so there is no reportable human efficacy evidence — just an unpublished trial plus an extensive rodent record. Total published human exposure for BPC-157 across all indications is only a few dozen subjects in small uncontrolled pilots. So IBD is simultaneously BPC-157's strongest case (discovered in the gut, decades of colitis data) and its weakest (its one shot at human IBD evidence produced no published result).
Can I use a peptide instead of, or to get off, my biologic?
No — and doing so is dangerous. Stopping or delaying effective IBD therapy risks flares, strictures, fistulae, hospitalization, surgery, and raises colorectal-cancer risk through uncontrolled inflammation. Under-treatment of IBD carries real, documented harm. Biologics and small molecules have Grade-A human evidence and are the guideline standard of care; peptides have no completed human IBD trials at all. Any change to your regimen must be made with, and monitored by, a board-certified gastroenterologist using objective markers such as fecal calprotectin, CRP and endoscopy. A peptide is not a substitute for a proven therapy.
Could peptides ever be used alongside a biologic?
Possibly in theory, but not in practice today. Barrier repair (larazotide) or tolerance induction (thymosin alpha-1) could conceptually complement immune suppression, and KPV's targeting of inflamed epithelium via PepT1 is mechanistically elegant. But there are no human IBD combination trials, and thymosin alpha-1 in particular stimulates T-cell and dendritic-cell activity, so it could theoretically counteract the very immunosuppression a biologic provides. This is a hypothesis, not an established practice, and it would only be appropriate under specialist supervision within a formal clinical trial — never as self-experimentation.
Is leaky gut the root cause of IBD that larazotide can fix?
Increased intestinal permeability is a real, early feature of Crohn's disease — present even before symptoms — and zonulin, the tight-junction regulator, is elevated in both Crohn's and ulcerative colitis, so barrier repair is a legitimate root-cause target. Larazotide antagonizes the zonulin pathway and promotes tight-junction reassembly. But the leading barrier peptide failed to beat placebo on the objective urinary lactulose-to-mannitol permeability endpoint, and then failed its pivotal Phase 3 trial in celiac disease. So while the leaky-gut mechanism is plausible, 'seal the gut and cure IBD' is not supported by human data.
What are the biggest safety concerns with peptides in IBD specifically?
Three stand out. First, BPC-157 is pro-angiogenic via VEGFR2 and EGR-1, and IBD itself raises colorectal-cancer risk — chronically stimulating angiogenesis in an inflamed, dysplasia-prone colon is a biologically plausible, unstudied hazard. Second, thymosin alpha-1 augments Th1, CD8 and dendritic-cell activity and is a relative contraindication in deliberate immunosuppression, a category overlapping with many IBD patients on immunosuppressants. Third, grey-market research-chemical peptides have documented endotoxin, heavy-metal and mislabeling problems — an infection and contamination risk especially dangerous in immunosuppressed IBD patients. None of these peptides has a human IBD safety profile.